{"id":"maternal-zidovudine-lamivudine-lopinavir-ritonavir","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Lactic acidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zidovudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, while lopinavir-ritonavir is a protease inhibitor combination that blocks HIV protease. Together, they suppress HIV replication in maternal circulation and reduce the viral load transmitted to the fetus during pregnancy and delivery.","oneSentence":"This combination of antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication in pregnant women and prevent mother-to-child transmission.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:20.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of mother-to-child HIV transmission in pregnant women"},{"name":"HIV infection in pregnancy"}]},"trialDetails":[{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT02712801","phase":"PHASE4","title":"Antiretroviral Regime for Viral Eradication in Newborns","status":"COMPLETED","sponsor":"National Center for Women and Children's Health, China CDC","startDate":"2016-04","conditions":"HIV/AIDS and Infections","enrollment":600},{"nctId":"NCT01061151","phase":"PHASE3","title":"Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-03-01","conditions":"HIV Infections","enrollment":3747},{"nctId":"NCT00099632","phase":"PHASE2","title":"Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-03","conditions":"HIV Infections","enrollment":484},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00270296","phase":"PHASE2","title":"Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections","enrollment":730},{"nctId":"NCT00086359","phase":"PHASE3","title":"Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections","enrollment":19},{"nctId":"NCT02431975","phase":"PHASE4","title":"Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial","status":"COMPLETED","sponsor":"Columbia University","startDate":"2015-08","conditions":"HIV","enrollment":73},{"nctId":"NCT01125696","phase":"PHASE2","title":"Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-05","conditions":"HIV, Hepatitis B","enrollment":45},{"nctId":"NCT00307151","phase":"PHASE2","title":"Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2005-12","conditions":"HIV Infections","enrollment":452},{"nctId":"NCT00753324","phase":"PHASE4","title":"Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-05","conditions":"HIV Infections","enrollment":284},{"nctId":"NCT01088516","phase":"PHASE4","title":"Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa","status":"COMPLETED","sponsor":"University of Zambia","startDate":"2008-12","conditions":"HIV","enrollment":280},{"nctId":"NCT00424814","phase":"PHASE2, PHASE3","title":"Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2007-03","conditions":"HIV Infections","enrollment":105},{"nctId":"NCT00936195","phase":"PHASE3","title":"Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial","status":"WITHDRAWN","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2010-01","conditions":"HIV Infection, Pregnancy, Breastfeeding","enrollment":""},{"nctId":"NCT00164736","phase":"PHASE3","title":"Breastfeeding, Antiretroviral, and Nutrition Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2004-03","conditions":"HIV Infections","enrollment":2369}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Combivir tabs (zidovudine 300mg and lamivudine 150mg)","Aluvia tabs (lopinavir 200mg /ritonavir 50mg)"],"phase":"phase_3","status":"active","brandName":"Maternal zidovudine/lamivudine/lopinavir-ritonavir","genericName":"Maternal zidovudine/lamivudine/lopinavir-ritonavir","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication in pregnant women and prevent mother-to-child transmission. Used for Prevention of mother-to-child HIV transmission in pregnant women, HIV infection in pregnancy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}